MEDICAL AND PHARMACOLOGIC MANAGEMENT OF THE HIV-INFECTED CHILD

[1]  S. Pelton,et al.  Seroreversion in human immunodeficiency virus‐exposed but uninfected infants , 1995, The Pediatric infectious disease journal.

[2]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[3]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[4]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[5]  D. Brambilla,et al.  Blood culture in the first 6 months of life for the diagnosis of vertically transmitted human immunodeficiency virus infection. The Women and Infants Transmission Study Group. , 1994, The Journal of infectious diseases.

[6]  Y. Bryson,et al.  Factors predictive of maternal-fetal transmission of HIV-1-preliminary analysis of zidovudine given during pregnancy and/or delivery , 1994 .

[7]  Chee-Jen Chang,et al.  A 12‐month study of the effects of oral zidovudine on neurodevelopmental functioning in a cohort of vertically HIV‐infected inner‐city children , 1994, AIDS.

[8]  W. Scott,et al.  Clinical and immunological correlates of immune-complex-dissociated HIV-1 p24 antigen in HIV-1-infected children. , 1994, Journal of acquired immune deficiency syndromes.

[9]  A. Fauci,et al.  Multifactorial nature of human immunodeficiency virus disease: implications for therapy. , 1993, Science.

[10]  L. Mofenson,et al.  Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. , 1993, Journal of acquired immune deficiency syndromes.

[11]  M. Gwinn,et al.  Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. , 1993, JAMA.

[12]  S. Spector,et al.  Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. , 1993, The Journal of pediatrics.

[13]  D. Venzon,et al.  Pancreatitis in human immunodeficiency virus-infected children receiving dideoxyinosine. , 1993, Pediatrics.

[14]  C. Fletcher,et al.  Zalcitabine , 1993, The Annals of pharmacotherapy.

[15]  J. Bremer,et al.  Study of human immunodeficiency virus resistance to 2'-3'-dideoxyinosine and zidovudine in sequential isolates from pediatric patients on long-term therapy. , 1993, The Journal of infectious diseases.

[16]  S. Steinberg,et al.  2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. , 1993, The Journal of infectious diseases.

[17]  R. Husson,et al.  Combination treatment with azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection. , 1992, The Journal of pediatrics.

[18]  S. Hammer,et al.  Zidovudine: Five Years Later , 1992, Annals of Internal Medicine.

[19]  R. Husson,et al.  The use of nucleoside analogues in the treatment of HIV-infected children. , 1992, AIDS research and human retroviruses.

[20]  A. Plebani,et al.  Prognostic factors and survival in children with perinatal HIV-1 infection , 1992, The Lancet.

[21]  R. Yogev,et al.  Lymphocyte subsets in healthy children during the first 5 years of life. , 1992, JAMA.

[22]  K. Holmes,et al.  Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers. , 1992, The Journal of infectious diseases.

[23]  E. Walter,et al.  HIV-1 sensitivity to zidovudine and clinical outcome in children , 1992, The Lancet.

[24]  F. Balis,et al.  Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children. , 1992, The Journal of infectious diseases.

[25]  R. Husson,et al.  Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine. , 1992, American journal of ophthalmology.

[26]  R. Nussenblatt,et al.  Retinal lesions in children treated with dideoxyinosine. , 1992, The New England journal of medicine.

[27]  C. Greco,et al.  Prognosis in AZT myopathy , 1991, Neurology.

[28]  R. V. van Oers,et al.  Effects of recombinant human granulocyte colony‐stimulating factor on leucopenia in zidovudine‐treated patients with AIDS and AIDS related complex, a phase I/II study , 1991, British journal of haematology.

[29]  C. Crumpacker,et al.  Inhibition of immune functions by antiviral drugs. , 1991, The Journal of clinical investigation.

[30]  M. Wulfsohn,et al.  A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. , 1991, The New England journal of medicine.

[31]  H. Mitsuya,et al.  Hematologic effects of AIDS therapies. , 1991, Hematology/oncology clinics of North America.

[32]  D. Venzon,et al.  Dideoxyinosine in children with symptomatic human immunodeficiency virus infection , 1991 .

[33]  J. Falloon,et al.  Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. , 1990, The Journal of pediatrics.

[34]  M. Till,et al.  Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine? , 1990, Annals of internal medicine.

[35]  N. Abraham,et al.  Role of heme metabolism in AZT‐induced bone marrow toxicity , 1990, American journal of hematology.

[36]  M. Fischl,et al.  Recombinant human erythropoietin for patients with AIDS treated with zidovudine. , 1990, The New England journal of medicine.

[37]  Douglas D. Richman,et al.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial , 1990 .

[38]  M. Dalakas,et al.  Mitochondrial myopathy caused by long-term zidovudine therapy. , 1990, The New England journal of medicine.

[39]  A. Dunton,et al.  A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex. , 1990, Journal of acquired immune deficiency syndromes.

[40]  J. Sommadossi,et al.  Cellular pharmacology of 3'-azido-3'-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. , 1989, Molecular pharmacology.

[41]  J. Starrett,et al.  1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent. , 1989, Journal of medicinal chemistry.

[42]  B. Peddle,et al.  ZIDOVUDINE-ASSOCIATED MYOPATHY , 1988, The Lancet.

[43]  S. Broder,et al.  Pharmacokinetics of 2‘,3’‐Dideoxycytidine in Patients with AIDS and Related Disorders , 1988, Journal of clinical pharmacology.

[44]  E. Louie,et al.  Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. , 1988, The New England journal of medicine.

[45]  H. Mitsuya,et al.  PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT) , 1988, The Lancet.

[46]  T. Matsui,et al.  Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus , 1987, Antimicrobial Agents and Chemotherapy.

[47]  H. Mitsuya,et al.  Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Sommadossi,et al.  Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro , 1987, Antimicrobial Agents and Chemotherapy.

[49]  Broder,et al.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D W Barry,et al.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.